Last 7 days
9.7%
Last 30 days
1.1%
Last 90 days
-29.3%
Trailing 12 Months
-61.2%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2022-12-14 | Bellinger Andrew | acquired | 103,320 | 2.87 | 36,000 | cso & cmo |
2022-12-01 | Bellinger Andrew | sold | -19,851 | 22.95 | -865 | cso & cmo |
2022-11-29 | Dorval Allison | acquired | - | - | 1,875 | chief financial officer |
2022-11-29 | Dorval Allison | sold | -12,243 | 22.1 | -554 | chief financial officer |
2022-11-04 | GV 2017 GP, L.L.C. | sold | -1,512,810 | 31.1386 | -48,583 | - |
2022-11-04 | Yeshwant Krishna | sold | -1,512,810 | 31.1386 | -48,583 | - |
2022-11-04 | Yeshwant Krishna | sold | - | - | -48,583 | - |
2022-11-04 | GV 2017 GP, L.L.C. | sold | -1,512,800 | 31.1386 | -48,583 | - |
2022-11-04 | GV 2017 GP, L.L.C. | sold | - | - | -48,583 | - |
2022-11-03 | GV 2017 GP, L.L.C. | sold | - | - | -49,569 | - |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | new | - | 430,921 | 430,921 | -% |
2023-09-20 | BARCLAYS PLC | added | 11.46 | 706,000 | 2,275,000 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -1.45 | 3,912 | 17,811 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 10.78 | 299,503 | 979,406 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 9.44 | 980,201 | 3,298,200 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 1.57 | 1,216,080 | 5,007,710 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | added | 2.94 | 9,000 | 35,000 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 14.93 | 375,124 | 1,133,830 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | reduced | -3.94 | 282,950 | 1,418,810 | -% |
2023-08-14 | IFP Advisors, Inc | new | - | 304 | 304 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | singer james r | 8.1% | 5e+06 | SC 13G/A | |
Feb 14, 2023 | casdin capital, llc | 3.7% | 2,290,571 | SC 13G/A | |
Feb 13, 2023 | arch venture fund x, l.p. | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 6.19% | 3,812,024 | SC 13G | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 07, 2023 | state street corp | 7.26% | 4,471,049 | SC 13G | |
Feb 06, 2023 | wellington management group llp | 1.39% | 859,102 | SC 13G/A | |
Feb 14, 2022 | gv 2017, l.p. | 13.12% | 6,320,905 | SC 13G | |
Feb 14, 2022 | casdin capital, llc | 6.5% | 3,138,167 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 19, 2023 | 4 | Insider Trading | |
Sep 19, 2023 | 3 | Insider Trading | |
Aug 10, 2023 | 8-K | Current Report | |
Aug 10, 2023 | 10-Q | Quarterly Report |
88.3%
88.3%
86.7%
Y-axis is the maximum loss one would have experienced if Verve Therapeutics was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 |
Revenue | 47.4% | 5,438,000 | 3,689,500 | 1,941,000 | - | - |
Operating Expenses | 9.5% | 213,850,000 | 195,366,000 | 167,628,000 | 151,446,000 | 130,159,000 |
S&GA Expenses | 10.2% | 46,999,000 | 42,650,000 | 37,533,000 | 32,695,000 | 29,110,000 |
R&D Expenses | 9.3% | 166,851,000 | 152,716,000 | 130,095,000 | 118,751,000 | 101,049,000 |
EBITDA | 100.0% | - | -153,917,000 | -154,530,000 | - | - |
EBITDA Margin | 100.0% | - | -34.51 | -79.61 | - | - |
Earnings Before Taxes | -Infinity% | -215,228,000 | - | -157,334,000 | - | -163,784,000 |
EBT Margin | 100.0% | - | -35.28 | -81.06 | - | - |
Net Income | -7.3% | -192,233,000 | -179,196,000 | -157,387,000 | -147,639,000 | -125,198,000 |
Net Income Margin | 100.0% | - | -40.18 | -81.09 | -39.73 | - |
Free Cashflow | 100.0% | - | -151,620,000 | -135,564,000 | -126,728,000 | -117,273,000 |
Balance Sheet | (In Millions) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -7.1% | 589 | 634 | 679 | 673 | 324 | 349 | 384 | 411 | 427 | 78.00 |
Current Assets | -8.6% | 473 | 518 | 563 | 562 | 299 | 329 | 367 | 394 | 420 | 74.00 |
Cash Equivalents | -16.4% | 70.00 | 84.00 | 115 | 277 | 73.00 | 91.00 | 70.00 | 148 | 387 | 9.00 |
Net PPE | 0.9% | 21.00 | 21.00 | 19.00 | 15.00 | 12.00 | 11.00 | 7.00 | 7.00 | 6.00 | 4.00 |
Liabilities | -0.8% | 124 | 125 | 128 | 125 | 28.00 | 18.00 | 27.00 | 26.00 | 21.00 | 17.00 |
Current Liabilities | -1.6% | 33.00 | 34.00 | 35.00 | 29.00 | 26.00 | 15.00 | 22.00 | 20.00 | 9.00 | 7.00 |
Shareholder's Equity | -8.7% | 465 | 509 | 551 | 548 | 296 | 331 | 357 | 385 | 405 | - |
Retained Earnings | -13.6% | -450 | -396 | -344 | -303 | -257 | -217 | -186 | -155 | -132 | -66.54 |
Additional Paid-In Capital | 1.1% | 916 | 906 | 896 | 852 | 555 | 549 | 544 | 540 | 538 | 3.00 |
Shares Outstanding | 0.3% | 62.00 | 62.00 | 62.00 | 60.00 | 49.00 | 49.00 | 49.00 | 48.00 | 8.00 | 3.00 |
Cashflow (Last 12 Months) | (In Millions) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Cashflow From Operations | -15.4% | -159 | -137 | -122 | -117 | -109 | -96.25 | -77.88 | -64.81 | -49.78 | -48.59 | -35.26 | -25.30 | -27.93 | -7.44 |
Share Based Compensation | 12.8% | 30.00 | 26.00 | 22.00 | 19.00 | 15.00 | 11.00 | 7.00 | 5.00 | 3.00 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 |
Cashflow From Investing | 12.6% | -175 | -200 | -155 | -44.63 | -201 | -190 | -239 | -170 | 39.00 | 28.00 | -51.13 | -10.87 | -120 | -12.76 |
Cashflow From Financing | 0.2% | 331 | 330 | 329 | 291 | 1.00 | 284 | 377 | 376 | 377 | 125 | 93.00 | - | 185 | 18.00 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Income Statement [Abstract] | ||||
Collaboration Revenue | $ 2,093 | $ 0 | $ 3,497 | $ 0 |
Operating expenses: | ||||
Research and development | 47,260 | 33,125 | 94,370 | 57,614 |
General and administrative | 13,416 | 9,067 | 25,969 | 16,503 |
Total operating expenses | 60,676 | 42,192 | 120,339 | 74,117 |
Loss from operations | (58,583) | (42,192) | (116,842) | (74,117) |
Other (expense) income: | ||||
Change in fair value of success payment liability | (662) | 938 | 76 | 2,615 |
Interest and other income, net | 5,438 | 308 | 10,984 | 390 |
Total other income, net | 4,776 | 1,246 | 11,060 | 3,005 |
Loss before provision for income taxes | (53,807) | (40,946) | (105,782) | (71,112) |
Provision for income taxes | (176) | 0 | (176) | 0 |
Net loss | $ (53,983) | $ (40,946) | $ (105,958) | $ (71,112) |
Net loss per common share attributable to common stockholders, basic | $ (0.87) | $ (0.84) | $ (1.71) | $ (1.46) |
Net loss per common share attributable to common stockholders, diluted | $ (0.87) | $ (0.84) | $ (1.71) | $ (1.46) |
Weighted-average common shares used in net loss per share attributable to common stockholders, basic | 61,953,992 | 48,674,873 | 61,871,158 | 48,623,330 |
Weighted-average common shares used in net loss per share attributable to common stockholders, diluted | 61,953,992 | 48,674,873 | 61,871,158 | 48,623,330 |
Comprehensive Loss: | ||||
Net loss | $ (53,983) | $ (40,946) | $ (105,958) | $ (71,112) |
Other comprehensive income (loss): | ||||
Unrealized income (loss) on marketable securities | (517) | (206) | (60) | (710) |
Comprehensive loss | $ (54,500) | $ (41,152) | $ (106,018) | $ (71,822) |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 70,042 | $ 115,412 |
Marketable securities | 392,434 | 439,396 |
Collaboration receivable | 2,093 | 1,012 |
Prepaid expenses and other current assets | 8,497 | 7,339 |
Total current assets | 473,066 | 563,159 |
Property and equipment, net | 21,252 | 18,778 |
Restricted cash | 4,824 | 4,824 |
Operating lease right-of-use assets | 88,766 | 91,877 |
Other long term assets | 1,223 | 585 |
Total assets | 589,131 | 679,223 |
Current liabilities: | ||
Accounts payable | 3,146 | 2,424 |
Accrued expenses | 19,839 | 20,767 |
Lease liability, current portion | 10,046 | 11,904 |
Total current liabilities | 33,031 | 35,095 |
Long-term lease liability | 67,819 | 70,014 |
Success Payment Liability | 2,809 | 2,885 |
Deferred revenue non-current | 20,014 | 20,014 |
Other long term liabilities | 236 | 283 |
Total liabilities | 123,909 | 128,291 |
Commitments and contingencies (See Note 7 and Note 8) | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding | 0 | 0 |
Common stock, $0.001 par value; 200,000,000 shares authorized, 62,064,279 and 61,730,816 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 62 | 62 |
Additional paid-in capital | 916,109 | 895,801 |
Accumulated other comprehensive loss | (754) | (694) |
Accumulated deficit | (450,195) | (344,237) |
Total stockholders equity | 465,222 | 550,932 |
Total liabilities and stockholders' equity | $ 589,131 | $ 679,223 |